Holen Sie sich die Stockscreener-App
132.08
2.35%
3.03
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$129.05
Offen:
$128.45
24-Stunden-Volumen:
755.76K
Relative Volume:
0.88
Marktkapitalisierung:
$9.44B
Einnahmen:
$12.82B
Nettoeinkommen (Verlust:
$936.34M
KGV:
12.30
EPS:
10.74
Netto-Cashflow:
$1.47B
1W Leistung:
-6.01%
1M Leistung:
-7.34%
6M Leistung:
-23.21%
1J Leistung:
-8.04%
1-Tages-Spanne:
$128.28
$132.56
1-Wochen-Bereich:
$126.07
$137.12
52-Wochen-Spanne:
$126.07
$179.60
Davita Inc Stock (DVA) Company Profile
Firmenname
Davita Inc
Sektor
Branche
Telefon
310-536-2668
Adresse
2000 16TH STREET, DENVER, CO
Vergleichen Sie DVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DVA
Davita Inc
|
132.08 | 9.23B | 12.82B | 936.34M | 1.47B | 10.74 |
|
HCA
Hca Healthcare Inc
|
390.31 | 89.60B | 72.70B | 5.97B | 7.29B | 23.79 |
|
THC
Tenet Healthcare Corp
|
170.48 | 14.72B | 20.52B | 1.46B | 1.41B | 15.12 |
|
FMS
Fresenius Medical Care Ag Adr
|
24.20 | 14.15B | 20.92B | 666.06M | 1.85B | 1.1422 |
|
EHC
Encompass Health Corp
|
118.63 | 11.83B | 5.51B | 494.70M | 386.40M | 4.84 |
|
UHS
Universal Health Services Inc
|
175.21 | 10.92B | 16.08B | 1.20B | 1.06B | 17.82 |
Davita Inc Stock (DVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-06 | Eingeleitet | Barclays | Equal Weight |
| 2023-08-07 | Hochstufung | UBS | Neutral → Buy |
| 2022-11-01 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-10-31 | Herabstufung | UBS | Buy → Neutral |
| 2022-08-19 | Fortgesetzt | UBS | Buy |
| 2022-06-21 | Bestätigt | BofA Securities | Underperform |
| 2021-09-10 | Eingeleitet | Cowen | Market Perform |
| 2021-08-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-03-26 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-11-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-10-25 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2019-09-11 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-01-08 | Hochstufung | UBS | Sell → Neutral |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Buy |
| 2018-12-14 | Eingeleitet | Barclays | Overweight |
| 2018-11-28 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-11-16 | Eingeleitet | UBS | Sell |
| 2018-11-08 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2018-09-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2018-01-04 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-12-12 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2017-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2017-12-07 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2017-11-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-06-26 | Herabstufung | Jefferies | Buy → Hold |
| 2016-12-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Davita Inc Aktie (DVA) Neueste Nachrichten
DaVita Inc. (DVA) Stock Decline & Market AnalysisNews and Statistics - IndexBox
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock - ca.finance.yahoo.com
Do Wall Street Analysts Like DaVita Stock? - 富途牛牛
Office-based Labs Market Is Going to Boom | Major Giants DaVita, Mednax, Philips, GE Healthcare - openPR.com
Are Investors Undervaluing DaVita (DVA) Right Now? - Yahoo Finance
DaVita (DVA) Is Down 6.5% After Cyber Disruption and Lowered Outlook for US Treatment Volumes - simplywall.st
Truist Reduces PT on DaVita Inc. (DVA) from $170 to $164; Zacks Keeps ‘Hold’ Rating - MSN
Can DaVita’s (DVA) Share Buybacks Offset Mixed Q2 Earnings Trends? - simplywall.st
DaVita Inc. (DVA) Stock Forecasts - Yahoo Finance
DaVita Inc. (NYSE:DVA) Q2 2025 Earnings Call Transcript - MSN
DaVita price target lowered to $148 from $164 at Truist - TipRanks
Can DaVita Inc. be the next market leaderStock Radar with High Payoff - thegnnews.com
Barclays Updates DaVita (DVA) with Lower Price Target to $160 | - GuruFocus
DaVita Healthcare’s Resilient Earnings Call Amid Challenges - TipRanks
DaVita Shares Plunge 9% Amid 150% Volume Surge to $430M, Rank 264th in Market Activity - AInvest
DaVita 2025 Q2 Earnings Net Income Falls 8.2% Despite Revenue Growth - AInvest
DaVita Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands - The Globe and Mail
DaVita Inc. Stock Dives 8.5% on Declining Treatment Volumes and Forecast CutNews and Statistics - IndexBox
Why DaVita (DVA) Stock Is Nosediving - TradingView
Huge healthcare breach sees nearly a million patients hit following DaVita ransomware attackmake sure you're safe - TechRadar
Barclays Adjusts DaVita Price Target to $160 From $169 - MarketScreener
DaVita stock hits 52-week low at $131.09 amid market fluctuations - Investing.com Nigeria
Over 900K hit by DaVita ransomware hack - SC Media
DaVita 2025 Q2 Earnings Mixed Performance as Net Income Falls 8.2% - AInvest
Deutsche Bank Adjusts DaVita Price Target to $137 From $165, Maintains Hold Rating - MarketScreener
DaVita Inc. Exceeds Expectations with Strong Q2 2025 Revenue GrowthNews and Statistics - IndexBox
DaVita reiterates $2.01B–$2.16B adjusted operating income guidance for 2025 as cost controls offset volume headwinds - MSN
DaVita HealthCare: Q2 Earnings Snapshot - Greenwich Time
DaVita Inc (DVA) Q2 2025 Earnings Call Highlights: Navigating Challenges with Resilience and ... - Yahoo Finance
DaVita Inc (DVA) Q2 2025 Earnings Call Highlights: Navigating Ch - GuruFocus
DaVita Inc (DVA) Q2 2025 Earnings Call Highlights: Navigating Challenges with Resilience and ... By GuruFocus - Investing.com Canada
DaVita Earnings: Management Sticks to 2025 Guidance Despite Ongoing Challenges - Morningstar
DaVita (DVA) Q2 2025 Earnings Call Transcript - Fortune
DaVita Inc. (DVA): Mastering Capital Allocation in a High-Margin Dialysis Industry - AInvest
Strategic Cost Management as the Cornerstone of DaVita's Resilient Operational Performance in 2025 - AInvest
Can DaVita's Pattern of Revenue Outperformance Shape Its Broader Growth Narrative? (DVA) - simplywall.st
DaVita Outpaces Expectations Despite Cyberattack And Hurricane Setbacks - Finimize
Earnings call transcript: DaVita Q2 2025 beats estimates, stock dips - Investing.com
DaVita Inc reports results for the quarter ended June 30Earnings Summary - TradingView
DaVita’s (NYSE:DVA) Q2 Sales Beat Estimates - Yahoo Finance
DaVita HealthCare (DVA) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
DaVita beats quarterly profit on steady demand for dialysis services - MarketScreener
DAVITA INC. SEC 10-Q Report - TradingView
DaVita HealthCare Reports Strong Q2 Earnings, Surpassing ExpectationsNews and Statistics - IndexBox
DaVita Q2 Adjusted Earnings, Revenue Rise - MarketScreener
DaVita Inc Q2 2025 Earnings: Revenue Surpasses Estimates at $3.3 - GuruFocus
DaVita Inc. Q2 Sales Increase - Nasdaq
DaVita earnings beat by $0.17, revenue topped estimates By Investing.com - Investing.com South Africa
DaVita earnings beat by $0.17, revenue topped estimates - Investing.com Australia
DaVita Inc Q2 2025 Earnings: Revenue Surpasses Estimates at $3.38 Billion, Adjusted EPS Beats at $2.95 - GuruFocus
Finanzdaten der Davita Inc-Aktie (DVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):